Case Studies

Understanding payer willingness to pay for a novel dermatologic therapy

26/04/2023

Author:

Sarah Bailey
About the Author

Article Tags

Digital Health Digital Therapeutics Early Payer Dialogue HTA HTA Process Pricing

Share this article

Related articles

Analysis
19.08.2026
Europe’s First JCAs: Early Signals for Pricing &...

The publication of the first three EU Joint Clinical Assessments (JCAs) provides the first opportuni...

Read more
Articles
10.08.2026
The Hidden Risk in Pharma Pricing: When Poor Gover...

Pricing strategies rarely fail because of one decision. More often, price potential is gradually ero...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch